Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-02-2008 | Original Paper

Bendamustine induces G2 cell cycle arrest and apoptosis in myeloma cells: the role of ATM-Chk2-Cdc25A and ATM-p53-p21-pathways

Authors: Leander Gaul, Sonja Mandl-Weber, Philipp Baumann, Bertold Emmerich, Ralf Schmidmaier

Published in: Journal of Cancer Research and Clinical Oncology | Issue 2/2008

Abstract

Purpose

Multiple myeloma is a fatal hematological disease caused by malignant transformation of plasma cells. Bendamustine has been proven to be a potent alternative to melphalan in phase 3 studies, yet its molecular mode of action is still poorly understood.

Methods

The four-myeloma cell lines NCI-H929, OPM-2, RPMI-8226, and U266 were cultured in vitro. Apoptosis was measured by flow cytometry after annexin V FITC and propidium iodide staining. Cell cycle distribution of cells was determined by DNA staining with propidium iodide. Intracellular levels of (phosphorylated) proteins were determined by western blot.

Results

We show that bendamustine induces apoptosis with an IC50 of 35–65 μg/ml and with cleavage of caspase 3. Incubation with 10–30 μg/ml results in G2 cell cycle arrest in all four-cell lines. The primary DNA-damage signaling kinases ATM and Chk2, but not ATR and Chk1, are activated. The Chk2 substrate Cdc25A phosphatase is degraded and Cdc2 is inhibited by inhibitory phosphorylation of Tyr15 accompanied by increased cyclin B levels. Additionally, p53 activation occurs as phosphorylation of Ser15, the phosphorylation site for ATM. p53 promotes Cdc2 inhibition by upregulation of p21. Targeting of p38 MAPK by the selective inhibitor SB202190 significantly increases bendamustine induced apoptosis. Additionally, SB202190 completely abrogates G2 cell cycle arrest.

Conclusion

Bendamustine induces ATM-Chk2-Cdc2-mediated G2 arrest and p53 mediated apoptosis. Inhibition of p38 MAPK augments apoptosis and abrogates G2 arrest and can be considered as a new therapeutic strategy in combination with bendamustine.

Abraham RT (2001) Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev 15:2177–2196PubMedCrossRef

Agner J, Falck J, Lukas J, Bartek J (2005) Differential impact of diverse anticancer chemotherapeutics on the Cdc25A-degradation checkpoint pathway. Exp Cell Res 302:162–169PubMedCrossRef

Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF et al (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 335:91–97PubMedCrossRef

Bode AM, Dong Z (2006) The enigmatic effects of caffeine in cell cycle and cancer. Cancer Lett 247:26–39PubMedCrossRef

Bozko P, Sabisz M, Larsen AK, Skladanowski A (2005) Cross-talk between DNA damage and cell survival checkpoints during G2 and mitosis: pharmacologic implications. Mol Cancer Ther 4:2016–2025PubMedCrossRef

Bulavin DV, Higashimoto Y, Popoff IJ, Gaarde WA, Basrur V, Potapova O et al (2001) Initiation of a G2/M checkpoint after ultraviolet radiation requires P38 kinase. Nature 411:102–107PubMedCrossRef

Buscemi G, Perego P, Carenini N, Nakanishi M, Chessa L, Chen J et al (2004) Activation of ATM and Chk2 kinases in relation to the amount of DNA strand breaks. Oncogene 23:7691–7700PubMedCrossRef

Busino L, Chiesa M, Draetta GF, Donzelli M (2004) Cdc25A phosphatase: combinatorial phosphorylation, ubiquitylation and proteolysis. Oncogene 23:2050–2056PubMedCrossRef

Canman CE, Lim DS, Cimprich KA, Taya Y, Tamai K, Sakaguchi K et al (1998) Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 281:1677–1679PubMedCrossRef

Chaturvedi P, Eng WK, Zhu Y, Mattern MR, Mishra R, Hurle MR et al (1999) Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway. Oncogene 18:4047–4054PubMedCrossRef

Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K et al (2003) Medical Research Council Adult Leukaemia Working Party. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348:1875–1883PubMedCrossRef

Damia G, Broggini M (2004) Cell cycle checkpoint proteins and cellular response to treatment by anticancer agents. Cell cycle 3:46–50PubMed

Falk J, Mailand N, Syljuasen RG, Bartek J, Lukas J (2001) The ATM-Chk2-cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature 410:842–847CrossRef

Garner AP, Weston CR, Todd DE, Balmanno K, Cook SJ (2002) Delta MEKK3:ER* activation induces a p38 alpha/beta 2-dependent cell cycle arrest at the G2 checkpoint. Oncogene 21:8089–8104PubMedCrossRef

Heider A, Niederle N (2001) Efficacy and toxicity of bendamustine in patients with relapsed low-grade Non Hodgkin’s lymphomas. Anticancer Drugs 12:725–729PubMedCrossRef

Herold M, Schulze A, Niederwieser D, Franke A, Fricke HJ, Richter P et al. for the East German Study Group Hematology and Oncology (OSHO) (2006). Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin`s lymphoma and mantle cell lymphoma: results of a randomised phase 3 trial (OSHO# 19). J Cancer Res Clin Oncol 132:105–112

Hideshima T, Akiyama M, Hayashi T, Richardson P, Schlossman R, Chauhan D et al (2003) Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu. Blood 101:703–705PubMedCrossRef

Hideshima T, Podar K, Chauhan D, Ishitsuka K, Mitsiades C, Tai YT et al (2004) P38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. Oncogene 23:8766–8776PubMedCrossRef

Hirao A, Kong YY, Matsuoka S, Wakeham A, Ruland J, Yoshida H et al (2000) DNA-damage induced activation o P53 by the checkpoint kinase Chk2. Science 287:1824–1827PubMedCrossRef

Hoffken K, Merkle K, Schonfelder M, Anger G, Brandtner M, Ridwelski K, Seeber S (1998) Bendamustine as salvage treatment in patients with advanced progressive breast cancer: a phase II study. J Cancer Res Clin Oncol 124:627–632PubMedCrossRef

Kath R, Blumenstengel K, Fricke HJ, Hoffken K (2001) Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia. J Cancer Res Clin Oncol 127:48–54PubMedCrossRef

Konstantinov SM, Kostovski A, Topashka-Ancheva M, Genova M, Berger MR (2002) Cytotoxic efficacy of bendamustine in human leukemia and breast cancer cell lines. J Cancer Res Clin Oncol 128:271–278PubMedCrossRef

Knop S, Straka C, Haen M, Schwedes R, Hebart H, Einsele H (2005) The eficiacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy. Haematologica 90:1287–1288PubMed

Leoni L, Bailey B, Reifert J, Niemeyer C, Bendall H, Dauffenbach L, Kerfoot C (2003) SDX-105 (Bendamustine), a clinically active antineoplastic agent possesses a unique mechanism of action. Blood 102(11):534-II

Lissitchkov T, Arnaudov G, Peytchev D, Merkle Kh (2006) Phase-I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy. J Cancer Res Clin Oncol 132:99–104PubMedCrossRef

Liu Q, Guntuku S, Cui XS, Matsuoka S, Cortez D, Tamai K et al (2000) Chk1 is an essential kinase that is regulated by Atr and required for the G2/M DNA damage checkpoint. Genes Dev 14:1448–1459PubMedCrossRef

Matsuoka S, Huang M, Elledge SJ (1998) Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science 282:1893–1897PubMedCrossRef

Mailand N, Falck J, Lukas C, Syljuåsen RG, Welcker M, Bartek J et al (2000) Rapid destruction of human Cdc25A in response to DNA damage. Science 288:1425–1429PubMedCrossRef

Maity A, Hwang A, Janss A, Phillips P, McKenna WG, Muschel RJ (1996) Delayed cyclin B1 expression during the G2 arrest following DNA damage. Oncogene 13:1647–1657PubMed

Miyakoda M, Suzuki K, Kodama S, Watanabe M (2002) Activation of ATM and phosphorylation of p53 by heat shock. Oncogene 21:1090–1096PubMedCrossRef

Myeloma Trialists’ Collaborative Group (1998) Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J Clin Oncol 16:3832–3842

Navas TA, Nguyen AN, Hideshima T, Reddy M, Ma JY, Haghnazari E et al (2006) Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo. Leukemia 20:1017–1027PubMedCrossRef

Nguyen AN, Stebbins EG, Henson M, O’Young G, Choi SJ, Quon D et al (2006) Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation. Exp Cell Res 312:1909–1923PubMedCrossRef

Nurse P (1990) Universal control mechanism regulating onset of M-phase. Nature 344:503–508PubMedCrossRef

O’Driscoll M, Ruiz-Perez VL, Woods CG, Jeggo PA, Goodship JA (2003) A splicing mutation affecting expression of ataxia-telangiectasia and Rad3-related protein (ATR) results in Seckel syndrome. Nat Genet 33:497–501PubMedCrossRef

Pedraza-Alva G, Koulnis M, Charland C, Thornton T, Clements JL, Schlissel MS et al (2006) Activation of p38 MAP kinase by DNA double-strand breaks in V(D)J recombination induces a G2/M cell cycle checkpoint. EMBO J 25:763–773PubMedCrossRef

Palumbo A, Bringhen S, Petrucci MT, Musto P, Rossini F, Nunzi M et al (2004) Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood 104:3052–3057PubMedCrossRef

Ponisch W, Mitrou PS, Merkle K, Herold M, Assmann M, Wilhelm G et al (2006) Treatment of bendamustine and prednisolone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with Melphalan and Prednisone—a randomised phase 3 study of the East German Study group of Hematology and Oncology (OSHO). J Cancer Res Clin Oncol 132:205–212PubMedCrossRef

Sanchez Y, Wong C, Thoma RS, Richman R, Wu Z, Piwnica-Worms H, Elledge SJ (1997) Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25. Science 277:1497–1501PubMedCrossRef

Sarkaria JN, Busby EC, Tibbets RS, Roos P, Taya Y, Karnitz LM et al (1999) Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Res 59:4375–4382PubMed

Strumberg D, Harstrick A, Doll K, Hoffmann B, Seeber S (1996) Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines. Anticancer Drugs 7:415–421PubMedCrossRef

Tibbetts RS, Brumbaugh KM, Williams JM, Sarkaria JN, Cliby WA, Shieh SY et al (1999) A role for ATR in the DNA damage-induced phosphorylation of p53. Genes Dev 13:152–157PubMed

Turenne GA, Paul P, Laflair L, Price BD (2001) Activation of p53 transcriptional activity requires ATM’s kinase domain and multiple N-terminal serine residues of p53. Oncogene 20:5100–5110PubMedCrossRef

von Minckwitz G, Chernozemsky I, Sirakova L, Chilingirov P, Souchon R, Marschner N et al (2005) Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC. Anticancer Drugs 16:871–877CrossRef

Wang S, Yang J, Qian J, Wezeman M, Kwak LW, Yi Q (2006) Tumor evasion of the immune system: inhibiting p38 MAPK signaling restores the function of dendritic cells in multiple myeloma. Blood 107:2432–2439PubMedCrossRef

Yamane K, Taylor K, Kinsella TJ (2004) Mismatch repair-mediated G2/M arrest by 6-thioguanine involves the ATR-Chk1 pathway. Biochem Biophys Res Commun 318:297–302PubMedCrossRef

Yan T, Desai AB, Jacobberger JW, Sramkoski RM, Loh T, Kinsella TJ (2004) CHK1 and CHK2 are differentially involved in mismatch repair-mediated 6-thioguanine-induced cell cycle checkpoint responses. Mol Cancer Ther 3:1147–1157PubMed

Zulkowski K, Kath R, Semrau R, Merkle K, Hoffken K (2002) Regression of brain metastases from breast carcinoma after chemotherapy with bendamustine. J Cancer Res Clin Oncol 128:111–113PubMedCrossRef

Title: Bendamustine induces G2 cell cycle arrest and apoptosis in myeloma cells: the role of ATM-Chk2-Cdc25A and ATM-p53-p21-pathways
Authors: Leander Gaul
Sonja Mandl-Weber
Philipp Baumann
Bertold Emmerich
Ralf Schmidmaier
Publication date: 01-02-2008
Publisher: Springer-Verlag
Published in: Journal of Cancer Research and Clinical Oncology / Issue 2/2008
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-007-0278-x

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2008

Livin and Bcl-2 expression in high-grade osteosarcoma

Toenail zinc level and gastric cancer risk in Cali, Colombia

Lymphatic and/or blood vessel invasion in gastric cancer: relationship with clinicopathological parameters, biological factors and prognostic significance

Human NAD(P)H:quinone oxidoreductase 1 (NQO1) and sulfotransferase 1A1 (SULT1A1) polymorphisms and urothelial cancer risk in Taiwan

Palliative gastrectomy and chemotherapy for stage IV gastric cancer

The association between RAD18 Arg302Gln polymorphism and the risk of human non-small-cell lung cancer

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials